Shanghai, China

Zhu Wang

This inventor holds 3 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent. Top assignee: Ampsource Biopharma Shanghai Inc.. Active years: 2021-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhu Wang. Retrieved from https://idiyas.com/inventor/zhu-wang-5y1qz84c

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 9.2

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Zhu Wang in Biopharmaceuticals

Introduction

Zhu Wang is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biopharmaceuticals. With a total of three patents to his name, he has made remarkable advancements in the development of fusion proteins and therapeutic antibodies.

Latest Patents

One of Zhu Wang's latest patents is titled "Linker peptide for constructing fusion protein." This invention describes a linker peptide that comprises both a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units, while the rigid peptide includes a human chorionic gonadotropin β-subunit carboxy-terminal peptide (CTP) with multiple glycosylation sites. This innovative linker peptide effectively reduces steric hindrance between two fusion molecules, thereby minimizing the loss of polymerization or activity due to improper protein folding. Additionally, the negatively charged, highly sialylated CTP enhances the half-life and bioavailability of the fused protein by resisting renal clearance.

Another significant patent by Zhu Wang is "Anti-human NGF antibodies and methods using same." This invention provides an antibody or antigen-binding fragment that specifically binds to nerve growth factor (NGF). The antibody exhibits high affinity for NGF and effectively blocks the interaction between NGF and its receptor. This capability makes it suitable for treating pain diseases associated with elevated NGF expression.

Career Highlights

Zhu Wang is currently employed at Ampsource Biopharma Shanghai Inc., where he continues to innovate in the biopharmaceutical sector. His work focuses on developing novel therapeutic solutions that address critical medical needs.

Collaborations

Zhu Wang collaborates with talented colleagues, including Qiang Li and Si Ruo Chen, to further enhance the impact of their research and innovations in the field.

Conclusion

Zhu Wang's contributions to biopharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work not only addresses significant health challenges but also paves the way for future developments in therapeutic treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…